Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
More than 5 million adults in the United States have undiagnosed type 2 diabetes mellitus, and another 38 million with pre-diabetes are at increased risk for developing diabetes. The lack of a simple and reliable way to detect diabetes and pre-diabetes has hindered identification of these individuals and provision of effective therapies. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) encourages the application of proteomic and other novel technologies to develop new diagnostic tests and/or to identify new biomarkers for the diagnosis of pre-diabetes and/or diabetes that do not require fasting or glucose administration.
Diabetes is a metabolic disease characterized by hyperglycemia that in 2002 affected nearly 9% of U.S. adults. More than 90% of the people with diabetes have type 2 diabetes. The symptoms of type 2 diabetes develop gradually. Some people have no symptoms until after they develop complications, which could have been prevented or delayed with early diagnosis and effective treatment. Additionally, 38 million U.S. adults aged 40-74 have pre-diabetes. Pre-diabetes is defined as impaired fasting glucose or impaired glucose tolerance (http://www.diabetes.org/diabetes-prevention/ pre-diabetes.jsp). These individuals have glucose levels above normal but below the level needed for diagnosis of diabetes. They are at increased risk of cardiovascular disease compared to those with normal glucose tolerance, and are at substantial risk for developing diabetes.
Clinical trials have demonstrated effective interventions for …
Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information: Article title: Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes. Contributors: Not available. Journal title: Environmental Health Perspectives. Volume: 112. Issue: 6 Publication date: May 2004. Page number: A372. © 2006 National Institute of Environmental Health Sciences. COPYRIGHT 2004 Gale Group.
This material is protected by copyright and, with the exception of fair use, may not be further copied, distributed or transmitted in any form or by any means.